Proton Pump Inhibitors Use in Patients With Ischemic Stroke on Dual Antiplatelet Therapy at Low Risk of Upper Gastrointestinal Bleeding
Journal of the American Heart Association · 07.01.2025 · 14 (1)
DOI: 10.1161/jaha.124.035239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 07.01.2025. Verfasst von Minyoul Baik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Yongin Severance Hospital Yonsei University College of Medicine Yongin-si Gyeonggi-do South Korea. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Gastrointestinal Hemorrhage, Platelet Aggregation Inhibitors, Ischemic Stroke. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Current guidelines lack recommendations regarding the use of proton pump inhibitors (PPIs) for preventing upper gastrointestinal bleeding (UGIB) among patients at low risk for UGIB treated with dual antiplatelet therapy for ischemic stroke (IS). Our objective was to assess the effectiveness of PPIs in lowering the risk of significant UGIB in this patient group. Methods and Results A retrospective cohort study was conducted involving patients at low risk for UGIB admitted for IS between 2014 and 2018 and treated with dual antiplatelet therapy. The study used a nationwide claims database in Korea. The primary end point was significant UGIB during 12 months after IS. To evaluate the risk of significant UGIB based on PPI use, we performed a multivariable Cox regression analysis. Subgroup analyses and propensity score matching analysis were conducted for validation. Among 96 722 patients with IS at low risk for UGIB who were on dual antiplatelet therapy (mean age, 67.0 years; men: 63.0%), 16 084 (16.6%) were treated with PPIs. During 12 months of follow‐up, 325 patients experienced significant UGIB, and 479 experienced any UGIB. PPI use was associated with a reduced risk of significant UGIB (hazard ratio, 0.63 [95% CI, 0.45–0.89]; P =0.009). This association was consistent in the subgroup and propensity score matching analyses.
Conclusions
In patients with IS receiving dual antiplatelet therapy, PPI use reduced the risk of significant UGIB by 37% on average, even among low‐risk patients. However, the use of PPIs in this patient group was limited, highlighting the need for additional prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Yongin Severance Hospital Yonsei University College of Medicine Yongin-si Gyeonggi-do South Korea.
- Division of Biostatistics, Department of Biomedical Systems Informatics Yonsei University College of Medicine Seoul Republic of Korea.
ORCID-Profile: Minyoul Baik, Seok-Jae Heo, Jinkwon Kim, Joonsang Yoo
Zitieren
APA
Baik, M., Jeon, J., Heo, S. J., Kim, J., & Yoo, J. (2025). Proton Pump Inhibitors Use in Patients With Ischemic Stroke on Dual Antiplatelet Therapy at Low Risk of Upper Gastrointestinal Bleeding. Journal of the American Heart Association, 14(1). https://doi.org/10.1161/jaha.124.035239
Vancouver
Baik M, Jeon J, Heo SJ, Kim J, Yoo J. Proton Pump Inhibitors Use in Patients With Ischemic Stroke on Dual Antiplatelet Therapy at Low Risk of Upper Gastrointestinal Bleeding. Journal of the American Heart Association. 2025;14(1). doi:10.1161/jaha.124.035239
BibTeX
@article{Baik2025,
author = {Baik, Minyoul and Jeon, Jimin and Heo, Seok-Jae and Kim, Jinkwon and Yoo, Joonsang},
title = {Proton Pump Inhibitors Use in Patients With Ischemic Stroke on Dual Antiplatelet Therapy at Low Risk of Upper Gastrointestinal Bleeding},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {1},
doi = {10.1161/jaha.124.035239}
}
EUVIMED